Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.

Remy P, Doder M, Lees A, Turjanski N, Brooks D.

Brain. 2005 Jun;128(Pt 6):1314-22. Epub 2005 Feb 16.

PMID:
15716302
2.

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P.

Brain. 2010 Apr;133(Pt 4):1111-27. doi: 10.1093/brain/awq032. Epub 2010 Mar 17.

PMID:
20237128
3.

The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.

Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, Le Bars D, Schmitt E, Bichon A, Pelissier P, Fraix V, Castrioto A, Sgambato-Faure V, Broussolle E, Tremblay L, Thobois S.

Brain. 2016 Sep;139(Pt 9):2486-502. doi: 10.1093/brain/aww162. Epub 2016 Aug 17.

PMID:
27538418
4.

Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.

Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ.

Brain. 2010 Nov;133(11):3434-43. doi: 10.1093/brain/awq268. Epub 2010 Sep 30.

PMID:
20884645
5.

Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease.

Chung SJ, Lee JJ, Ham JH, Lee PH, Sohn YH.

Parkinsonism Relat Disord. 2016 Feb;23:62-5. doi: 10.1016/j.parkreldis.2015.12.003. Epub 2015 Dec 17.

PMID:
26717857
6.

Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography.

Becker T, Becker G, Seufert J, Hofmann E, Lange KW, Naumann M, Lindner A, Reichmann H, Riederer P, Beckmann H, Reiners K.

J Neurol Neurosurg Psychiatry. 1997 Nov;63(5):590-6.

7.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.

J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40.

8.

In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease.

Murai T, Müller U, Werheid K, Sorger D, Reuter M, Becker T, von Cramon DY, Barthel H.

J Neuropsychiatry Clin Neurosci. 2001 Spring;13(2):222-8.

PMID:
11449029
9.

Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease.

Tedroff J, Aquilonius SM, Hartvig P, Lundqvist H, Gee AG, Uhlin J, Långström B.

Acta Neurol Scand. 1988 Mar;77(3):192-201.

PMID:
3259784
10.
11.

Dopamine in amygdala gates limbic processing of aversive stimuli in humans.

Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, Smolka MN, Gründer G, Cumming P, Kumakura Y, Bartenstein P, Dolan RJ, Heinz A.

Nat Neurosci. 2008 Dec;11(12):1381-2. doi: 10.1038/nn.2222. Epub 2008 Nov 2.

PMID:
18978778
13.

Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of a depression scale (MADRS) in Parkinson's disease.

Koerts J, Leenders KL, Koning M, Portman AT, van Beilen M.

Eur J Neurosci. 2007 May;25(10):3132-6.

PMID:
17561826
14.

Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease.

Hu X, Song X, Yuan Y, Li E, Liu J, Liu W, Liu Y.

Mov Disord. 2015 Feb;30(2):238-44. doi: 10.1002/mds.26087. Epub 2014 Dec 27.

PMID:
25545969
15.

PET imaging of neocortical monoaminergic terminals in Parkinson's disease.

Marié RM, Barré L, Rioux P, Allain P, Lechevalier B, Baron JC.

J Neural Transm Park Dis Dement Sect. 1995;9(1):55-71.

PMID:
7605590
16.

Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders.

Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R.

Brain. 2007 Jul;130(Pt 7):1799-807. Epub 2007 Feb 28.

PMID:
17329323
17.

Noradrenaline in Parkinson's disease: from disease progression to current therapeutics.

Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A.

Curr Med Chem. 2007;14(22):2330-4. Review.

PMID:
17896981
18.

Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.

Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Tanaka K.

Brain. 2001 Apr;124(Pt 4):784-92.

PMID:
11287377
20.

Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.

Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ.

Brain. 2008 May;131(Pt 5):1294-302. doi: 10.1093/brain/awn054. Epub 2008 Mar 24.

PMID:
18362097

Supplemental Content

Support Center